You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Author Index Volume 56 (2017)

The issue number is given in front of the pagination

Aarsland, D., see Bergland, A.K. (2) 575–584

Aarsland, D., see Chong, J.R. (1) 157–166

Abrescia, P., see Benussi, L. (2) 825–833

Adolfsson, O., see Theunis, C. (2) 585–599

Agüera-Ortiz, L., see Ismail, Z. (3) 929–938

Agyemang, C., I.E. van de Vorst, H.L. Koek, M.L. Bots, A. Seixas, M. Norredam, U. Ikram, K. Stronks and I. Vaartjes, Ethnic Variations in Prognosis of Patients with Dementia: A Prospective Nationwide Registry Linkage Study in The Netherlands (1) 205–213

Ahmed, M.E., see Lu, Y. (4) 1469–1484

Ahonen, R., see Koponen, M. (1) 107–118

Aisen, P.S., see Sokolow, S. (1) 229–237

Aizenstein, O., see Molad, J. (4) 1293–1299

Akatsu, H., see Sabbagh, M.N. (2) 441–446

Akazawa, K., see Kuriyama, N. (4) 1253–1262

Akiba, C., see Jurjević, I. (1) 317–325

Alcolea, D., see Tell-Marti, G. (3) 1065–1074

Alegret, M., see Boada, M. (1) 129–143

Allen, M., see N’Songo, A. (4) 1215–1222

Almkvist, O., see Li, X. (1) 327–334

Alperin, N., see Loewenstein, D.A. (3) 1119–1126

Ambrosi, A., ses Ferrari, L. (3) 1101–1107

Amen, D.G., B. Darmal, C.A. Raji, W. Bao, L. Jorandby, S. Meysami and C.S. Raghavendra, Discriminative Properties of Hippocampal Hypoperfusion in Marijuana Users Compared to Healthy Controls: Implications for Marijuana Administration in Alzheimer’s Dementia (1) 261–273

Amenta, F., see Carotenuto, A. (2) 805–815

Amin, N.D., see Shukla, V. (1) 335–349

An, H., see Kim, Y.J. (3) 1007–1014

Anand, K., see Sabbagh, M.N. (2) 441–446

Anaya, F., see Boada, M. (1) 129–143

Angus, J.A., see Betrie, A.H. (2) 849–860

Anstey, K.J., K. Ashby-Mitchell and R. Peters, Updating the Evidence on the Association between Serum Cholesterol and Risk of Late-Life Dementia: Review and Meta-Analysis (1) 215–228

Antonell, A., see Tell-Marti, G. (3) 1065–1074

Apostolova, I., C. Lange, A. Roberts, H.J. Igel, A. Mäurer, S. Liese, M. Estrella, V. Prasad, E. Stechl, G. Lämmler, E. Steinhagen-Thiessen and R. Buchert, Challenges in Screening and Recruitment for a Neuroimaging Study in Cognitively Impaired Geriatric Inpatients (1) 197–204

Apostolova, L.G., see Sokolow, S. (1) 229–237

Arai, H., see Jurjević, I. (1) 317–325

Araujo, J.A., see Borghys, H. (2) 763–774

Archetti, S., see Ferrari, R. (4) 1271–1278

Arighi, A., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Arnold, S.E., see Yarchoan, M. (2) 699–706

Artyuhov, A.S., see Dashinimaev, E.B. (2) 835–847

Arvanitakis, Z., see Yarchoan, M. (2) 699–706

Ashby-Mitchell, K., see Anstey, K.J. (1) 215–228

Ashe, K.H., see Liu, P. (2) 743–761

Asmann, Y., see N’Songo, A. (4) 1215–1222

Asthana, S., see Law, L.L. (1) 351–359

Attems, J., see Chong, J.R. (1) 157–166

Audoin, B., see Sellal, F. (1) 37–46

Auger, L.E., see Last, N. (1) 275–286

Auriel, E., see Molad, J. (4) 1293–1299

Avila, J., see Gomez-Ramos, A. (3) 977–990

Axmacher, N., see Kunz, L. (3) 1135–1144

Ayres, A., see Valenti, R. (4) 1223–1227

Ayton, S., see Betrie, A.H. (2) 849–860

Baazaoui, N., M. Flory and K. Iqbal, Synaptic Compensation as a Probable Cause of Prolonged Mild Cognitive Impairment in Alzheimer’s Disease: Implications from a Transgenic Mouse Model of the Disease (4) 1385–1401

Bäckman, L., see Khan, W. (3) 1159–1174

Badenas, C., see Tell-Marti, G. (3) 1065–1074

Bagnoli, S., see Ferrari, R. (4) 1271–1278

Bai, F., see Su, F. (2) 491–507

Baldeiras, I., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Ballard, C.G., see Chong, J.R. (1) 157–166

Banaschewski, T., see Khan, W. (3) 1159–1174

Bao, W., see Amen, D.G. (1) 261–273

Barão, S., see Timmers, M. (4) 1437–1449

Barcs, G., see Horváth, A. (3) 1175–1183

Barker, G.J., see Khan, W. (3) 1159–1174

Barkhof, F., see Louwersheimer, E. (1) 63–74

Baroni, M., see Boccardi, V. (1) 239–248

Barrett, M.S., see Siegel, A.M.

Barrio, J.R., see Doran, E. (2) 459–470

Barthel, H., see Sabbagh, M.N. (2) 441–446

Bastian, F.O., Combined Creutzfeldt-Jakob/Alzheimer’s Disease Cases are Important in Search for Microbes in Alzheimer’s Disease (3) 867–876

Batchelor, J., see McKinnon, A.C. (4) 1373–1384

Bautz, A., see Thygesen, L.C. (4) 1429–1435

Behrens, T.W., see Haddick, P.C.G. (3) 1037–1054

Belliard, S., see Gaubert, M. (2) 717–731

Ben Assayag, E., see Molad, J. (4) 1293–1299

Ben Bashat, D., see Molad, J. (4) 1293–1299

Bendlin, B.B., see Law, L.L. (1) 351–359

Benedí, J., see González-Muñoz, M.J. (3) 917–927

Bennett, D.A., see Yarchoan, M. (2) 699–706

Bennett, D.A., see Yu, L. (4) 1485–1493

Benussi, L., R. Ghidoni, F.D. Piaz, G. Binetti, G. Di Iorio and P. Abrescia, The level of 24-Hydroxycholesteryl Esters is an Early Marker of Alzheimer’s Disease (2) 825–833

Benussi, L., see Ferrari, R. (4) 1271–1278

Bergland, A.K., I. Dalen, A.I. Larsen, D. Aarsland and H. Soennesyn, Effect of Vascular Risk Factors on the Progression of Mild Alzheimer’s Disease and Lewy Body Dementia (2) 575–584

Bernardi, L., see Ferrari, R. (4) 1271–1278

Betrie, A.H., S. Ayton, A.I. Bush, J.A. Angus, P. Lei, C.E. Wright, Evidence of a Cardiovascular Function for Microtubule-Associated Protein Tau (2) 849–860

Bhangale, T.R., see Haddick, P.C.G. (3) 1037–1054

Bhati, M.T., see Siegel, A.M.

Biegon, A., see Sundermann, E.E. (3) 947–957

Bielarczyk, H., see Zyśk, M. (3) 1145–1158

Binetti, G., see Benussi, L. (2) 825–833

Binetti, G., see Ferrari, R. (4) 1271–1278

Binukumar, B.K., see Shukla, V. (1) 335–349

Blennow, K., see Li, X. (1) 327–334

Blennow, K., see Toombs, J. (3) 885–891

Blennow, K., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Blusztajn, J.K., see Wang, E. (1) 47–61

Boada, M., F. Anaya, P. Ortiz, J. Olazarán, J.R. Shua-Haim, T.O. Obisesan, I. Hernández, J. Muñoz, M. Buendia, M. Alegret, A. Lafuente, L. Tárraga, L. Núñez, M. Torres, J.R. Grifols, I. Ferrer, O.L. Lopez and A. Páez, Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer’s Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial (1) 129–143

Boccardi, V., M. Baroni, N. Smirne, A. Clodomiro, S. Ercolani, A. Longo, C. Ruggiero, A.C. Bruni and P. Mecocci, Short-Term Response is not Predictive of Long-Term Response to Acetylcholinesterase Inhibitors in Old Age Subjects with Alzheimer’s Disease: A “Real World” Study (1) 239–248

Bocti, C., see Castellano, C.-A. (4) 1459–1468

Boddaert, J., see Zerah, L. (1) 145–156

Bogert, J., see Timmers, M. (4) 1437–1449

Bohlken, J., see Jacob, L. (1) 379–384

Bohlken, J., see Jacob, L. (4) 1519–1524

Bokde,A.L.W., see Khan, W. (3) 1159–1174

Bolshakov, A.P., see Dashinimaev, E.B. (2) 835–847

Bondi, M.W., see Granholm, E.L. (4) 1419–1428

Bonomi, E., see Ferrari, R. (4) 1271–1278

Boots, E.A., see Law, L.L. (1) 351–359

Borchelt, D.R., see Liu, P. (2) 743–761

Borghgraef, P., see Theunis, C. (2) 585–599

Borghys, H., B. Van Broeck, D. Dhuyvetter, T. Jacobs, K. de Waepenaert, T. Erkens, M. Brooks, S. Thevarkunnel and J.A. Araujo, Young to Middle-Aged Dogs with High Amyloid-β Levels in Cerebrospinal Fluid are Impaired on Learning in Standard Cognition tests (2) 763–774

Bornstein, N.M., see Molad, J. (4) 1293–1299

Borroni, B., see Ferrari, R. (4) 1271–1278

Borsello, T., see Buccarello, L. (4) 1279–1292

Bots, M.L., see Agyemang, C. (1) 205–213

Boulouis, G., see Valenti, R. (4) 1223–1227

Bouwman, F.H., see Slot, R.E.R. (2) 687–697

Boyle, P.A., see Yu, L. (4) 1485–1493

Bozzali, M., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Brandscheid, C., F. Schuck, S. Reinhardt, K.-H. Schäfer, C.U. Pietrzik, M. Grimm, T. Hartmann, A. Schwiertz and K. Endres, Altered Gut Microbiome Composition and Tryptic Activity of the 5xFAD Alzheimer’s Mouse Model (2) 775–788

Brann, D., see Lu, Y. (4) 1469–1484

Bremer, J.A.E., see Van Mierlo, L.D. (1) 249–259

Brodaty, H., see Ismail, Z. (3) 929–938

Brooks, M., see Borghys, H. (2) 763–774

Brooks, S.W., A.C. Dykes and B.G. Schreurs, A High-Cholesterol Diet Increases 27-Hydroxycholesterol and Modifies Estrogen Receptor Expression and Neurodegeneration in Rabbit Hippocampus (1) 185–196

Bruce, D.G., see Peters, K.E. (3) 1127–1133

Bruni, A.C., see Boccardi, V. (1) 239–248

Bruni, A.C., see Ferrari, R. (4) 1271–1278

Buccarello, L., G. Grignaschi, A.M. Castaldo, A. Di Giancamillo, C. Domeneghini, R.C. Melcangi and T. Borsello, Sex Impact on Tau-Aggregation and Postsynaptic Protein Levels in the P301L Mouse Model of Tauopathy (4) 1279–1292

Büchel, C., see Khan, W. (3) 1159–1174

Buchert, R., see Apostolova, I. (1) 197–204

Buendia, M., see Boada, M. (1) 129–143

Bush, A.I., see Betrie, A.H. (2) 849–860

Caga, J., see Kaizik, C. (3) 1109–1117

Cai, J., see Li, L. (4) 1403–1417

Caltagirone, C., see Gelfo, F. (4) 1505–1518

Calvo-Garrido, J., see Persson, T. (2) 601–617

Camino, J., see Kaizik, C. (3) 1109–1117

Campion, D., see Sellal, F. (1) 37–46

Caon, M., see Ienca, M. (4) 1301–1340

Capp, K., see Loewenstein, D.A. (3) 1119–1126

Carlsson, C.M., see Law, L.L. (1) 351–359

Carotenuto, A., R. Rea, E. Traini, A.M. Fasanaro, G. Ricci, V. Manzo and F. Amenta, The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer’s Disease: Interim Results of the ASCOMALVA Trial (2) 805–815

Carrasquillo, M.M., see N’Songo, A. (4) 1215–1222

Carter, A.Y., see Fitz, N.F. (3) 1075–1085

Casson, R.J., see Chidlow, G. (2) 655–675

Castagna, A., see Gareri, P. (2) 557–565

Castaldo, A.M., see Buccarello, L. (4) 1279–1292

Castellano, C.-A., N. Paquet, I.J. Dionne, H. Imbeault, F. Langlois, E. Croteau, S. Tremblay, M. Fortier, J.J. Matte, G. Lacombe, T. Fülöp, C. Bocti and S.C. Cunnane, A 3-Month Aerobic Training Program Improves Brain Energy Metabolism in Mild Alzheimer’s Disease: Preliminary Results from a Neuroimaging Study (4) 1459–1468

Castelo-Branco, M., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Castranio, E.L., see Fitz, N.F. (3) 1075–1085

Cavedo, E., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Cedazo-Mínguez, Á., see Persson, T. (2) 601–617

Chai, Y.L., see Chong, J.R. (1) 157–166

Chang, K.J., C.H. Hong, K.S. Lee, D.R. Kang, J.D. Lee, S.H. Choi, S.Y. Kim, D.L. Na, S.W. Seo, D.-K. Kim, Y. Lee, Y.K. Chung, K.Y. Lim, J.S. Noh, J. Park and S.J. Son, Mortality Risk after Diagnosis of Early-Onset Alzheimer’s Disease versus Late-Onset Alzheimer’s Disease: A Propensity Score Matching Analysis (4) 1341–1348

Charidimou, A., see Valenti, R. (4) 1223–1227

Chen, C., see Shen, L. (1) 361–378

Chen, C.P., see Chong, J.R. (1) 157–166

Chen, J., L. Zhan, X. Lu, C. Xiao and N. Sun, The Alteration of ZiBuPiYin Recipe on Proteomic Profiling of Forebrain Postsynaptic Density of db/db Mice with Diabetes-Associated Cognitive Decline (2) 471–489

Chen, L., see Sokolow, S. (1) 229–237

Chen, Y., see Shen, L. (1) 361–378

Chételat, G., see Gaubert, M. (2) 717–731

Chidlow, G., J.P.M. Wood, J. Manavis, J. Finnie and R.J. Casson, Investigations into Retinal Pathology in the Early Stages of a Mouse Model of Alzheimer’s Disease (2) 655–675

Choi, S.H., see Chang, K.J. (4) 1341–1348

Chong, J.R., Y.L. Chai, J.H. Lee, D. Howlett, J. Attems, C.G. Ballard, D. Aarsland, P.T. Francis, C.P. Chen and M.K.P. Lai, Increased Transforming Growth Factor β2 in the Neocortex of Alzheimer’s Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble Aβ42 Load (1) 157–166

Chung, Y.K., see Chang, K.J. (4) 1341–1348

Cieslak, A., see Ismail, Z. (3) 929–938

Claassen, J.A.H.R., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Clarimón, J., see Tell-Marti, G. (3) 1065–1074

Clodomiro, A., see Boccardi, V. (1) 239–248

Cohen-Bittan, J., see Zerah, L. (1) 145–156

Cohn-Hokke, P.E., see Louwersheimer, E. (1) 63–74

Colao, R., see Ferrari, R. (4) 1271–1278

Comi, G., ses Ferrari, L. (3) 1101–1107

Conforti, R., see Gareri, P. (2) 557–565

Conrod, P., see Khan, W. (3) 1159–1174

Cook, D.B., see Law, L.L. (1) 351–359

Coppedè, F., see Stoccoro, A. (4) 1451–1457

Cotroneo, A.M., see Gareri, P. (2) 557–565

Crespo-Biel, N., see Theunis, C. (2) 585–599

Crocco, E., see Loewenstein, D.A. (3) 1119–1126

Cross, N.E., see McKinnon, A.C. (4) 1373–1384

Croteau, E., see Castellano, C.-A. (4) 1459–1468

Cruchaga, C., see Haddick, P.C.G. (3) 1037–1054

Cui, D., see Xie, B. (1) 391–401

Cui, M.-Z., see Hu, C. (4) 1263–1269

Cummings, J., see Ismail, Z. (3) 929–938

Cunnane, S.C., see Castellano, C.-A. (4) 1459–1468

Cupidi, C., see Ferrari, R. (4) 1271–1278

Curiel, R.E., see Loewenstein, D.A. (3) 1119–1126

Curiel, R.E., see Matías-Guiu, J.A. (2) 733–742

Cutuli, D., see Gelfo, F. (4) 1505–1518

Czaja, S.J., see Loewenstein, D.A. (3) 1119–1126

D’Amelio, M., see Gelfo, F. (4) 1505–1518

Dai, S.-X., see Wang, Q. (4) 1525–1539

Dai, Z., see Wang, Z. (1) 415–428

Dalen, I., see Bergland, A.K. (2) 575–584

Darmal, B., see Amen, D.G. (1) 261–273

Dartigues, J.-F., see Pimouguet, C. (2) 509–517

Dashinimaev, E.B., A.S. Artyuhov, A.P. Bolshakov, E.A. Vorotelyak and A.V. Vasiliev, Neurons Derived from Induced Pluripotent Stem Cells of Patients with Down Syndrome Reproduce Early Stages of Alzheimer’s Disease Type Pathology in vitro (2) 835–847

Davidsdottir, S., see Valenti, R. (4) 1223–1227

Davis, T.M.E., see Peters, K.E. (3) 1127–1133

Davis, W.A., see Peters, K.E. (3) 1127–1133

De Bartolo, P., see Gelfo, F. (4) 1505–1518

de la Monte, S., see Lee, H.-K. (3) 1015–1036

de La Sayette, V., see Gaubert, M. (2) 717–731

de Oliveira, C.R., see van Waalwijk van Doorn, L.J.C. (2) 543–555

de Strooper, B., see Timmers, M. (4) 1437–1449

de Waepenaert, K., see Borghys, H. (2) 763–774

De Waepenaert, K., see Timmers, M. (4) 1437–1449

Desgranges, B., see Gaubert, M. (2) 717–731

Devijver, H., see Theunis, C. (2) 585–599

Dhar, A., see Sellal, F. (1) 37–46

Dhuyvetter, D., see Borghys, H. (2) 763–774

Di Giancamillo, A., see Buccarello, L. (4) 1279–1292

Di Iorio, G., see Benussi, L. (2) 825–833

Dionne, I.J., see Castellano, C.-A. (4) 1459–1468

DiPucchio, Z.Y., see Sellal, F. (1) 37–46

Domeneghini, C., see Buccarello, L. (4) 1279–1292

Dong, J., see Wu, L. (3) 893–898

Dong, Y., see Lu, Y. (4) 1469–1484

Doody, R.S., see Jia, J. (4) 1495–1504

Doran, E., D. Keator, E. Head, M.J. Phelan, R. Kim, M. Totoiu, J.R. Barrio, G.W. Small, S.G. Potkin and I.T. Lott, Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer’s Disease: The Role of APP (2) 459–470

Dougherty, R.J., see Law, L.L. (1) 351–359

Doumpoulakis, S., see Zygouris, S. (2) 619–627

Dowling, N.M., see Law, L.L. (1) 351–359

Duara, R., see Loewenstein, D.A. (3) 1119–1126

Duara, R., see N’Songo, A. (4) 1215–1222

Duffy, S.L., see McKinnon, A.C. (4) 1373–1384

Dykes, A.C., see Brooks, S.W. (1) 185–196

Dyś, A., see Zyśk, M. (3) 1145–1158

Ebel, D.L., C.G. Torkilsen and T.D. Ostrowski, Blunted Respiratory Responses in the Streptozotocin-Induced Alzheimer’s Disease Rat Model (3) 1197–1211

Edwards, D.F., see Law, L.L. (1) 351–359

Egret, S., see Gaubert, M. (2) 717–731

Einerson, J.A., see Law, L.L. (1) 351–359

Elger, B., see Ienca, M. (4) 1301–1340

Elman, J.A., see Granholm, E.L. (4) 1419–1428

Emek-Savaş, D.D., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Emon, M.A.E.K., A.T. Kodamullil, R. Karki, E. Younesi and M. Hofmann-Apitius, Using Drugs as Molecular Probes: A Computational Chemical Biology Approach in Neurodegenerative Diseases (2) 677–686

Endres, K., see Brandscheid, C. (2) 775–788

Engelborghs, S., see Timmers, M. (4) 1437–1449

Ercolani, S., see Boccardi, V. (1) 239–248

Eren, E., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Erkens, T., see Borghys, H. (2) 763–774

Ertekin-Taner, N., see N’Songo, A. (4) 1215–1222

Escott-Price, V., see Morgan, A.R. (1) 25–36

Estrella, M., see Apostolova, I. (1) 197–204

Eusebi, P., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Eustache, F., see Gaubert, M. (2) 717–731

Fabrice, J., see Ienca, M. (4) 1301–1340

Fang, H., see Fenesi, B. (1) 297–303

Farotti, L., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Farrer, L.A., see Haddick, P.C.G. (3) 1037–1054

Fasanaro, A.M., see Carotenuto, A. (2) 805–815

Fenesi, B., H. Fang, A. Kovacevic, M. Oremus, P. Raina and J.J. Heisz, Physical Exercise Moderates the Relationship of Apolipoprotein E (APOE) Genotype and Dementia Risk: A Population-Based Study (1) 297–303

Feng, N., see Li, L. (4) 1403–1417

Feng, R., see Li, L. (4) 1403–1417

Fenoglio, C., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Fernández-Castro, A., see Matías-Guiu, J.A. (2) 733–742

Fernández-Matarrubia, M., see Matías-Guiu, J.A. (2) 733–742

Fernández-Santiago, R., see Tell-Marti, G. (3) 1065–1074

Ferrari, L., S.-C. Huang, G. Magnani, A. Ambrosi, G. Comi and L. Leocani, Optical Coherence Tomography Reveals Retinal Neuroaxonal Thinning in Frontotemporal Dementia as in Alzheimer’s Disease (3) 1101–1107

Ferrari, R., M. Grassi, F. Graziano, F. Palluzzi, S. Archetti, E. Bonomi, A.C. Bruni, R.G. Maletta, L. Bernardi, C. Cupidi, R. Colao, I. Rainero, E. Rubino, L. Pinessi, D. Galimberti, E. Scarpini, M. Serpente, B. Nacmias, I. Piaceri, S. Bagnoli, G. Rossi, G. Giaccone, F. Tagliavini, L. Benussi, G. Binetti, R. Ghidoni, A. Singleton, J. Hardy, P. Momeni, A. Padovani and B. Borroni, Effects of Multiple Genetic Loci on Age at Onset in Frontotemporal Dementia (4) 1271–1278

Ferrer, I., see Boada, M. (1) 129–143

Ferri, R., see Stoccoro, A. (4) 1451–1457

Finnie, J., see Chidlow, G. (2) 655–675

Fischer, C.E., see Hird, M.A. (2) 447–452

Fischer, C.E., see Ismail, Z. (3) 929–938

Fitz, N.F., A.Y. Carter, V. Tapias, E.L. Castranio, R. Kodali, I. Lefterov and R. Koldamova, ABCA1 Deficiency Affects Basal Cognitive Deficits and Dendritic Density in Mice (3) 1075–1085

Flor, H., see Khan, W. (3) 1159–1174

Flory, M., see Baazaoui, N. (4) 1385–1401

Foiani, M.S., see Toombs, J. (3) 885–891

Forster, C.L., see Liu, P. (2) 743–761

Fortea, J., see Tell-Marti, G. (3) 1065–1074

Fortier, M., see Castellano, C.-A. (4) 1459–1468

Fotiadis, P., see Valenti, R. (4) 1223–1227

Fox, N.C., see Toombs, J. (3) 885–891

Francis, P.T., see Chong, J.R. (1) 157–166

Franz, C.E., see Granholm, E.L. (4) 1419–1428

Fratiglioni, L., see Khan, W. (3) 1159–1174

Frebourg, T., see Sellal, F. (1) 37–46

Freund-Levi, Y., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Frisoni, G.B., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Frommann, I., see Polcher, A. (3) 1185–1196

Frosch, M., see Sellal, F. (1) 37–46

Frouin, V., see Khan, W. (3) 1159–1174

Fujishima, M., A. Kawaguchi, N. Maikusa, R. Kuwano, T. Iwatsubo, H. Matsuda for the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI), Sample Size Estimation for Alzheimer’s Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging (1) 75–88

Fülöp, T., see Castellano, C.-A. (4) 1459–1468

Gafner, V., see Theunis, C. (2) 585–599

Galimberti, D., see Ferrari, R. (4) 1271–1278

Galimberti, D., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Gallagher, C.L., see Law, L.L. (1) 351–359

Gallinat, J., see Khan, W. (3) 1159–1174

Gamez, M., see Loewenstein, D.A. (3) 1119–1126

Gapys, B., see Zyśk, M. (3) 1145–1158

Garavan, H., see Khan, W. (3) 1159–1174

García, E., see Gomez-Ramos, A. (3) 977–990

Garcimartín, A., see González-Muñoz, M.J. (3) 917–927

Gareri, P., A. Castagna, A.M. Cotroneo, D. Putignano, R. Conforti, F. Santamaria, S. Marino and S. Putignano, The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer’s Disease Study (2) 557–565

Garrido, P., see Gomez-Ramos, A. (3) 977–990

Gasse, C., see Nørgaard, A. (2) 707–716

Gaubert, M., N. Villain, B. Landeau, F. Mézenge, S. Egret, A. Perrotin, S. Belliard, V. de La Sayette, F. Eustache, B. Desgranges, G. Chételat and G. Rauchs, Neural Correlates of Self-Reference Effect in Early Alzheimer’s Disease (2) 717–731

Gauthier, S., see Ismail, Z. (3) 929–938

Geda, Y.E., see Ismail, Z. (3) 929–938

Gelfo, F., D. Cutuli, A. Nobili, P. De Bartolo, M. D’Amelio, L. Petrosini and C. Caltagirone, Chronic Lithium Treatment in a Rat Model of Basal Forebrain Cholinergic Depletion: Effects on Memory Impairment and Neurodegeneration (4) 1505–1518

Genc, S., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Gertz, H.-J., see Sabbagh, M.N. (2) 441–446

Ghidoni, R., see Benussi, L. (2) 825–833

Ghidoni, R., see Ferrari, R. (4) 1271–1278

Giaccone, G., see Ferrari, R. (4) 1271–1278

Giakoumis, D., see Zygouris, S. (2) 619–627

Giampietro, V., see Khan, W. (3) 1159–1174

Gill, D.P., see Heath, M. (1) 167–183

Gillen, D.L., see Grill, J.D. (3) 939–946

Gimsing, L.N., see Thygesen, L.C. (4) 1429–1435

Gispert, J.D., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Glozman, T., J. Solomon, F. Pestilli and L. Guibas, for the Alzheimer’s Disease Neuroimaging Initiative, Shape-Attributes of Brain Structures as Biomarkers for Alzheimer’s Disease (1) 287–295

Goate, A.M., see Haddick, P.C.G. (3) 1037–1054

Goff, M.L., see Pimouguet, C. (2) 509–517

Gombert, C., see Sellal, F. (1) 37–46

Gomez-Ramos, A., A.J. Picher, E. García, P. Garrido, F. Hernandez, E. Soriano and J. Avila, Validation of Suspected Somatic Single Nucleotide Variations in the Brain of Alzheimer’s Disease Patients (3) 977–990

Gong, Y., see Li, L. (4) 1403–1417

González-Muñoz, M.J., A. Garcimartín, I. Meseguer, C.J. Mateos-Vega, J.M. Orellana, A. Peña-Fernández, J. Benedí and F.J. Sánchez-Muniz, Silicic Acid and Beer Consumption Reverses the Metal Imbalance and the Prooxidant Status Induced by Aluminum Nitrate in Mouse Brain (3) 917–927

Gower, A.C., see Wang, E. (1) 47–61

Gowland, P., see Khan, W. (3) 1159–1174

Graff, C., see Li, X. (1) 327–334

Graff-Radford, N., see N’Songo, A. (4) 1215–1222

Graham, R.R., see Haddick, P.C.G. (3) 1037–1054

Graham, S.J., see Hird, M.A. (2) 447–452

Granholm, E.L., M.S. Panizzon, J.A. Elman, A.J. Jak, R.L. Hauger, M.W. Bondi, M.J. Lyons, C.E. Franz and W.S. Kremen, Pupillary Responses as a Biomarker of Early Risk for Alzheimer’s Disease (4) 1419–1428

Grant, P., see Shukla, V. (1) 335–349

Grassi, M., see Ferrari, R. (4) 1271–1278

Graziano, F., see Ferrari, R. (4) 1271–1278

Greco, V., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Greenberg, S.M., see Sellal, F. (1) 37–46

Greenberg, S.M., see Valenti, R. (4) 1223–1227

Greig Custo, M.T., see N’Songo, A. (4) 1215–1222

Grifols, J.R., see Boada, M. (1) 129–143

Grignaschi, G., see Buccarello, L. (4) 1279–1292

Grill, J.D., A. Holbrook, A. Pierce, D. Hoang and D.L. Gillen, Attitudes toward Potential Participant Registries (3) 939–946

Grimm, M., see Brandscheid, C. (2) 775–788

Grunstein, R.R., see McKinnon, A.C. (4) 1373–1384

Guibas, L., see Glozman, T. (1) 287–295

Gul-Hinc, S., see Zyśk, M. (3) 1145–1158

Guo, Q., see Wang, Z. (1) 415–428

Guo, Y., see Shen, L. (1) 361–378

Guo, Y.-C., see Wang, Q. (4) 1525–1539

Gurol, M.E., see Valenti, R. (4) 1223–1227

Ha, A.Y., see Lee, H.-K. (3) 1015–1036

Haddick, P.C.G., J.L. Larson, N. Rathore, T.R. Bhangale, Q.T. Phung, K. Srinivasan, D.V. Hansen, J.R. Lill, Alzheimer’s Disease Genetic Consortium (ADGC), Alzheimer’s Disease Neuroimaging Initiative (ADNI), M.A. Pericak-Vance, J. Haines, L.A. Farrer, J.S. Kauwe, G.D. Schellenberg, C. Cruchaga, A.M. Goate, T.W. Behrens, R.J. Watts, R.R. Graham, J.S. Kaminker and M. van der Brug, A Common Variant of IL-6R is Associated with Elevated IL-6 Pathway Activity in Alzheimer’s Disease Brains (3) 1037–1054

Haines, J., see Haddick, P.C.G. (3) 1037–1054

Hall, A., see Suhonen, N.-M. (4) 1241–1251

Hallikainen, I., see Suhonen, N.-M. (4) 1241–1251

Ham, L.S., see Meijboom, R. (2) 789–804

Hampel, H., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Han, F.-F., see Wang, Q. (4) 1525–1539

Hannequin, D., see Sellal, F. (1) 37–46

Hänninen, T., see Suhonen, N.-M. (4) 1241–1251

Hansen, D.V., see Haddick, P.C.G. (3) 1037–1054

Hansen, E.S., see Nørgaard, A. (2) 707–716

Hao, K., see Ho, L. (1) 305–315

Hardy, J., see Ferrari, R. (4) 1271–1278

Hariramani, R., see Matías-Guiu, J.A. (2) 733–742

Hartikainen, S., see Koponen, M. (1) 107–118

Hartikainen, S., see Lampela, P. (1) 119–128

Hartmann, T., see Brandscheid, C. (2) 775–788

Hashimoto, Y., see Kamikubo, Y. (2) 641–653

Hattori, N., see Jurjević, I. (1) 317–325

Hauger, R.L., see Granholm, E.L. (4) 1419–1428

He, Y., see Wang, Z. (1) 415–428

Head, E., see Doran, E. (2) 459–470

Heath, M., E. Shellington, S. Titheridge, D.P. Gill and R.J. Petrella, A 24-Week Multi-Modality Exercise Program Improves Executive Control in Older Adults with a Self-Reported Cognitive Complaint: Evidence from the Antisaccade Task (1) 167–183

Heinz, A., see Khan, W. (3) 1159–1174

Heisz, J.J., see Fenesi, B. (1) 297–303

Helmer, C., see Pimouguet, C. (2) 509–517

Hemmy, L.S., see Liu, P. (2) 743–761

Hermann, B.P., see Law, L.L. (1) 351–359

Hernandez, F., see Gomez-Ramos, A. (3) 977–990

Hernández, I., see Boada, M. (1) 129–143

Herrmann, N., see Ismail, Z. (3) 929–938

Herukka, S.-K., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Heslegrave, A., see Toombs, J. (3) 885–891

Hickie, I.B., see McKinnon, A.C. (4) 1373–1384

Hickman, D.T., see Theunis, C. (2) 585–599

Hietanen, M., see Kallio, E.-L. (4) 1349–1372

Hird, M.A., K.A. Vesely, C.E. Fischer, S.J. Graham, G. Naglie and T.A. Schweizer, Investigating Simulated Driving Errors in Amnestic Single- and Multiple-Domain Mild Cognitive Impairment (2) 447–452

Hisatsune, T., see Matsuda, T. (1) 1–23

Ho, L., M. Legere, T. Li, S. Levine, K. Hao, B. Valcarcel and G.M. Pasinetti, Autonomic Nervous System Dysfunctions as a Basis for a Predictive Model of Risk of Neurological Disorders in Subjects with Prior History of Traumatic Brain Injury: Implications in Alzheimer’s Disease (1) 305–315

Hoang, D., see Grill, J.D. (3) 939–946

Hodges, J.R., see Kaizik, C. (3) 1109–1117

Hofmann-Apitius, M., see Emon, M.A.E.K. (2) 677–686

Holbrook, A., see Grill, J.D. (3) 939–946

Holstege, H., see Louwersheimer, E. (1) 63–74

Hong, C.H., see Chang, K.J. (4) 1341–1348

Hong, X., see Wang, H. (3) 875–883

Horváth, A., A. Szűcs, G. Barcs and A. Kamondi, Sleep EEG Detects Epileptiform Activity in Alzheimer’s Disease with High Sensitivity (3) 1175–1183

Howlett, D., see Chong, J.R. (1) 157–166

Hsieh-Li, H.-M., see Lin, T.-S. (3) 959–976

Hu, C., J. Xu, L. Zeng, T. Li, M.-Z. Cui and X. Xu, Pen-2 and Presenilin are Sufficient to Catalyze Notch Processing (4) 1263–1269

Huang, E.S., see Liu, P. (2) 743–761

Huang, J.-F., see Wang, Q. (4) 1525–1539

Huang, R.-S., see Lin, T.-S. (3) 959–976

Huang, S.-C., ses Ferrari, L. (3) 1101–1107

Hulsman, M., see Louwersheimer, E. (1) 63–74

Hvidt, N.C., see Thygesen, L.C. (4) 1429–1435

Ienca, M., J. Fabrice, B. Elger, M. Caon, A.S. Pappagallo, R.W. Kressig and T. Wangmo, Intelligent Assistive Technology for Alzheimer’s Disease and Other Dementias: A Systematic Review (4) 1301–1340

Igel, H.J., see Apostolova, I. (1) 197–204

Ihara, M., see Kuriyama, N. (4) 1253–1262

Ikram, U., see Agyemang, C. (1) 205–213

Imbeault, H., see Castellano, C.-A. (4) 1459–1468

Imtiaz, B., A.M. Tolppanen, A. Solomon, H. Soininen and M. Kivipelto, Estradiol and Cognition in the Cardiovascular Risk Factors, Aging and Dementia (CAIDE) Cohort Study (2) 453–458

Innes, K.E., T.K. Selfe, D.S. Khalsa and S. Kandati, Meditation and Music Improve Memory and Cognitive Function in Adults with Subjective Cognitive Decline: A Pilot Randomized Controlled Trial (3) 899–916

Iqbal, K., see Baazaoui, N. (4) 1385–1401

Ismail, Z., L. Agüera-Ortiz, H. Brodaty, A. Cieslak, J. Cummings, C.E. Fischer, S. Gauthier, Y.E. Geda, N. Herrmann, J. Kanji, K.L. Lanctôt, D.S. Miller, M.E. Mortby, C.U. Onyike, P.B. Rosenberg, E.E. Smith, G.S. Smith, D.L. Sultzer and C. Lyketsos for the NPS Professional Interest Area of the International Society of to Advance Alzheimer’s Research and Treatment (NPS-PIA of ISTAART), The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations (3) 929–938

Itamura, K., see Lee, H.-K. (3) 1015–1036

Ittermann, B., see Khan, W. (3) 1159–1174

Iwata, N., see Matsunaga, S. (4) 1229–1239

Iwatsubo, T., see Fujishima, M. (1) 75–88

Jacob, L., J. Bohlken and K. Kostev, Prevalence of Use of Cardiovascular Drugs in Dementia Patients Treated in General Practices in Germany (4) 1519–1524

Jacob, L., J. Bohlken and K. Kostev, Risk Factors for Mild Cognitive Impairment in German Primary Care Practices (1) 379–384

Jacobs, T., see Borghys, H. (2) 763–774

Jak, A.J., see Granholm, E.L. (4) 1419–1428

James, B.D., see Yarchoan, M. (2) 699–706

Jaul, E. and O. Meiron, Dementia and Pressure Ulcers: Is There a Close Pathophysiological Interrelation? (3) 861–866

Jensen-Dahm, C., see Nørgaard, A. (2) 707–716

Jessen, F., see Polcher, A. (3) 1185–1196

Ji, H.-F., see Shen, L. (1) 385–390

Jia, J., C. Wei, L. Jia, Y. Tang, J. Liang, A. Zhou, F. Li, L. Shi and R.S. Doody, Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer’s Disease: A Randomized Controlled Trial (4) 1495–1504

Jia, J., see Wu, L. (3) 893–898

Jia, L., see Jia, J. (4) 1495–1504

Jiang, L., see Xie, B. (1) 391–401

Jiang, Y., see Tan, L. (2) 629–640

Johansen, C., see Thygesen, L.C. (4) 1429–1435

Johnson, S.C., see Law, L.L. (1) 351–359

Jokelainen, J., see Suhonen, N.-M. (4) 1241–1251

Jones, L., see Morgan, A.R. (1) 25–36

Jongbloed, W., see Slot, R.E.R. (2) 687–697

Jorandby, L., see Amen, D.G. (1) 261–273

Jovalekic, A., see Sabbagh, M.N. (2) 441–446

Jurjević, I., M. Miyajima, I. Ogino, C. Akiba, M. Nakajima, A. Kondo, M. Kikkawa, M. Kanai, N. Hattori and H. Arai, Decreased Expression of hsa-miR-4274 in Cerebrospinal Fluid of Normal Pressure Hydrocephalus Mimics with Parkinsonian Syndromes (1) 317–325

Kaddoumi, A., see Mohamed, L.A. (3) 1087–1099

Kaizik, C., J. Caga, J. Camino, C.M. O’Connor, C. McKinnon, J.R. Oyebode, O. Piguet, J.R. Hodges and E. Mioshi, Factors Underpinning Caregiver Burden in Frontotemporal Dementia Differ in Spouses and their Children (3) 1109–1117

Kallio, E.-L., H. Öhman, H. Kautiainen, M. Hietanen and K. Pitkälä, Cognitive Training Interventions for Patients with Alzheimer’s Disease: A Systematic Review (4) 1349–1372

Kalpouzos, G., see Khan, W. (3) 1159–1174

Kamikubo, Y., N. Takasugi, K. Niisato, Y. Hashimoto and T. Sakurai, Consecutive Analysis of BACE1 Function on Developing and Developed Neuronal Cells (2) 641–653

Kaminker, J.S., see Haddick, P.C.G. (3) 1037–1054

Kamondi, A., see Horváth, A. (3) 1175–1183

Kanai, M., see Jurjević, I. (1) 317–325

Kandati, S., see Innes, K.E. (3) 899–916

Kang, D.R., see Chang, K.J. (4) 1341–1348

Kanji, J., see Ismail, Z. (3) 929–938

Karagiannidis, C., see Zygouris, S. (2) 619–627

Karki, R., see Emon, M.A.E.K. (2) 677–686

Kautiainen, H., see Kallio, E.-L. (4) 1349–1372

Kauwe, J.S., see Haddick, P.C.G. (3) 1037–1054

Kawaguchi, A., see Fujishima, M. (1) 75–88

Keator, D., see Doran, E. (2) 459–470

Kesavapany, S., see Shukla, V. (1) 335–349

Kester, M.I., see Slot, R.E.R. (2) 687–697

Khalsa, D.S., see Innes, K.E. (3) 899–916

Khan, W., V. Giampietro, T. Banaschewski, G.J. Barker, A.L.W. Bokde, C. Büchel, P. Conrod, H. Flor, V. Frouin, H. Garavan, P. Gowland, A. Heinz, B. Ittermann, H. Lemaître, F. Nees, T. Paus, Z. Pausova, M. Rietschel, M.N. Smolka, A. Ströhle, J. Gallinat, B. Vellas, H. Soininen, I. Kloszewska, M. Tsolaki, P. Mecocci, C. Spenger, V.L. Villemagne, C.L. Masters, J.-S. Muehlboeck, L. Bäckman, L. Fratiglioni, G. Kalpouzos, L.-O. Wahlund, G. Schumann, S. Lovestone, S.C.R. Williams, E. Westman, A. Simmons, Alzheimer’s Disease Neuroimaging Initiative, AddNeuroMed Consortium, Australian, Imaging, Biomarkers, and Lifestyle Study Research Group and and the IMAGEN consortium, A Multi-Cohort Study of ApoE ɛ4 and Amyloid-β Effects on the Hippocampus in Alzheimer’s Disease (3) 1159–1174

Khiami, F., see Zerah, L. (1) 145–156

Kikkawa, M., see Jurjević, I. (1) 317–325

Kim, B., see Kim, Y.J. (3) 1007–1014

Kim, D.-K., see Chang, K.J. (4) 1341–1348

Kim, K.W., see Kim, Y.J. (3) 1007–1014

Kim, R., see Doran, E. (2) 459–470

Kim, S.Y., see Chang, K.J. (4) 1341–1348

Kim, Y.J., H. An, B. Kim, Y.S. Park and K.W. Kim, An International Comparative Study on Driving Regulations on People with Dementia (3) 1007–1014

Kishi, T., see Matsunaga, S. (4) 1229–1239

Kivipelto, M., see Imtiaz, B. (2) 453–458

Kliper, E., see Molad, J. (4) 1293–1299

Kloszewska, I., see Khan, W. (3) 1159–1174

Kodali, R., see Fitz, N.F. (3) 1075–1085

Kodamullil, A.T., see Emon, M.A.E.K. (2) 677–686

Koek, H.L., see Agyemang, C. (1) 205–213

Koene, T., see Louwersheimer, E. (1) 63–74

Koene, T., see Van Mierlo, L.D. (1) 249–259

Koldamova, R., see Fitz, N.F. (3) 1075–1085

Kondo, A., see Jurjević, I. (1) 317–325

Kondo, M., see Kuriyama, N. (4) 1253–1262

Koponen, M., H. Taipale, P. Lavikainen, A. Tanskanen, J. Tiihonen, A.-M. Tolppanen, R. Ahonen and S. Hartikainen, Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer’s Disease (1) 107–118

Koppara, A., see Polcher, A. (3) 1185–1196

Korcarz, C.E., see Law, L.L. (1) 351–359

Korczyn, A.D., see Molad, J. (4) 1293–1299

Koscik, R.L., see Law, L.L. (1) 351–359

Kostev, K., see Jacob, L. (1) 379–384

Kostev, K., see Jacob, L. (4) 1519–1524

Kotani, R., Y. Urano, H. Sugimoto and N. Noguchi, Decrease of Amyloid-β Levels by Curcumin Derivative via Modulation of Amyloid-β Protein Precursor Trafficking (2) 529–542

Kourkoulis, C.E., see Sellal, F. (1) 37–46

Kovacevic, A., see Fenesi, B. (1) 297–303

Kowall, N., see Wang, E. (1) 47–61

Koyama, T., see Kuriyama, N. (4) 1253–1262

Kremen, W.S., see Granholm, E.L. (4) 1419–1428

Kressig, R.W., see Ienca, M. (4) 1301–1340

Krüger, J., see Suhonen, N.-M. (4) 1241–1251

Kuijf, H.J., see Valenti, R. (4) 1223–1227

Kuiperij, H.B., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Kuntz, S., see Shukla, V. (1) 335–349

Kunz, L., M. Reuter, N. Axmacher and C. Montag, Conscientiousness is Negatively Associated with Grey Matter Volume in Young APOE ɛ4-Carriers (3) 1135–1144

Kuriyama, N., M. Ihara, T. Mizuno, E. Ozaki, D. Matsui, I. Watanabe, T. Koyama, M. Kondo, T. Tokuda, A. Tamura, K. Yamada, K. Akazawa, K. Takeda, A. Takada, S. Mizuno, M. Nakagawa and Y. Watanabe, Association between Mid-Regional Proadrenomedullin Levels and Progression of Deep White Matter Lesions in the Brain Accompanying Cognitive Decline (4) 1253–1262

Kuskowski, M.A., see Liu, P. (2) 743–761

Kuwano, R., see Fujishima, M. (1) 75–88

Kwon, B., see Lee, H.-K. (3) 1015–1036

Lacombe, G., see Castellano, C.-A. (4) 1459–1468

Lafuente, A., see Boada, M. (1) 129–143

Lagopoulos, J., see McKinnon, A.C. (4) 1373–1384

Lai, M.K.P., see Chong, J.R. (1) 157–166

Lämmler, G., see Apostolova, I. (1) 197–204

Lampela, P., A.-M. Tolppanen, A. Tanskanen, J. Tiihonen, S. Hartikainen and H. Taipale, Anticholinergic Exposure and Risk of Pneumonia in Persons with Alzheimer’s Disease: A Nested Case-Control Study (1) 119–128

Lanctôt, K.L., see Ismail, Z. (3) 929–938

Landau, S., see Sundermann, E.E. (3) 947–957

Landeau, B., see Gaubert, M. (2) 717–731

Lange, C., see Apostolova, I. (1) 197–204

Langlois, F., see Castellano, C.-A. (4) 1459–1468

Larsen, A.I., see Bergland, A.K. (2) 575–584

Larson, J.L., see Haddick, P.C.G. (3) 1037–1054

Last, N., E. Tufts and L.E. Auger, The Effects of Meditation on Grey Matter Atrophy and Neurodegeneration: A Systematic Review (1) 275–286

Lattanzio, F., see Persson, T. (2) 601–617

Lavikainen, P., see Koponen, M. (1) 107–118

Law, L.L., S.A. Schultz, E.A. Boots, J.A. Einerson, R.J. Dougherty, J.M. Oh, C.E. Korcarz, D.F. Edwards, R.L. Koscik, N.M. Dowling, C.L. Gallagher, B.B. Bendlin, C.M. Carlsson, S. Asthana, B.P. Hermann, M.A. Sager, S.C. Johnson, D.B. Cook, J.H. Stein and O.C. Okonkwo, Chronotropic Response and Cognitive Function in a Cohort at Risk for Alzheimer’s Disease (1) 351–359

Lee, C.-H., see Lin, T.-S. (3) 959–976

Lee, H.-K., B. Kwon, C.A. Lemere, S. de la Monte, K. Itamura, A.Y. Ha and H.W. Querfurth, mTORC2 (Rictor) in Alzheimer’s Disease and Reversal of Amyloid-β Expression-Induced Insulin Resistance and Toxicity in Rat Primary Cortical Neurons (3) 1015–1036

Lee, J.D., see Chang, K.J. (4) 1341–1348

Lee, J.H., see Chong, J.R. (1) 157–166

Lee, K.S., see Chang, K.J. (4) 1341–1348

Lee, Y., see Chang, K.J. (4) 1341–1348

Lefterov, I., see Fitz, N.F. (3) 1075–1085

Legere, M., see Ho, L. (1) 305–315

Lei, P., see Betrie, A.H. (2) 849–860

Lemaître, H., see Khan, W. (3) 1159–1174

Lemere, C.A., see Lee, H.-K. (3) 1015–1036

Leocani, L., ses Ferrari, L. (3) 1101–1107

Lethias, C., see Salza, R. (3) 991–1005

Levine, S., see Ho, L. (1) 305–315

Lewis, S.J.G., see McKinnon, A.C. (4) 1373–1384

Li, F., see Jia, J. (4) 1495–1504

Li, G.-H., see Wang, Q. (4) 1525–1539

Li, H., see Tan, L. (2) 629–640

Li, J., see Li, L. (4) 1403–1417

Li, J., see Wu, L. (3) 893–898

Li, L., S. Xu, L. Liu, R. Feng, Y. Gong, X. Zhao, J. Li, J. Cai, N. Feng, L. Wang, X. Wang and Y. Peng, Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-α and IL-1β in an Aβ25–35-induced Rat Model of Alzheimer’s Disease (4) 1403–1417

Li, S., see Shen, L. (1) 361–378

Li, T., see Ho, L. (1) 305–315

Li, T., see Hu, C. (4) 1263–1269

Li, W.-X., see Wang, Q. (4) 1525–1539

Li, X., E. Westman, S. Thordardottir, A.K. Ståhlbom, O. Almkvist, K. Blennow, L.-O. Wahlund and C. Graff, The Effects of Gene Mutations on Default Mode Network in Familial Alzheimer’s Disease (1) 327–334

Li, X., see Sokolow, S. (1) 229–237

Liang, J., see Jia, J. (4) 1495–1504

Liang, M.-C., see Lin, T.-S. (3) 959–976

Liao, L., see Shen, L. (1) 361–378

Liese, S., see Apostolova, I. (1) 197–204

Lill, J.R., see Haddick, P.C.G. (3) 1037–1054

Lim, K.Y., see Chang, K.J. (4) 1341–1348

Lin, T.-S., H.-J. Tsai, C.-H. Lee, Y.-Q. Song, R.-S. Huang, H.-M. Hsieh-Li, M.-C. Liang and Y. Lin, An Improved Drugs Screening System Reveals that Baicalein Ameliorates the Aβ/AMPA/NMDA-Induced Depolarization of Neurons (3) 959–976

Lin, Y., see Lin, T.-S. (3) 959–976

Lipton, R.B., see Sundermann, E.E. (3) 947–957

Liu, D., see Wang, Z. (1) 415–428

Liu, J., see Wu, L. (3) 893–898

Liu, L., see Li, L. (4) 1403–1417

Liu, L., see Shen, L. (1) 385–390

Liu, P., J.H. Reichl, E.R. Rao, B.M. McNellis, E.S. Huang, L.S. Hemmy, C.L. Forster, M.A. Kuskowski, D.R. Borchelt, R. Vassar, K.H. Ashe and K.R. Zahs, Quantitative Comparison of Dense-Core Amyloid Plaque Accumulation in Amyloid-β Protein Precursor Transgenic Mice (2) 743–761

Liu, Q., see Shen, L. (1) 361–378

Liu, W., see Tan, L. (2) 629–640

Liu, W., see Xie, B. (1) 391–401

Liu, Y., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Liu, Z., see Xie, B. (1) 391–401

Lladó, A., see Tell-Marti, G. (3) 1065–1074

Lladó, A., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Lleó, A., see Tell-Marti, G. (3) 1065–1074

Lleó, A., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Loewenstein, D.A., R.E. Curiel, C. Wright, X. Sun, N. Alperin, E. Crocco, S.J. Czaja, A. Raffo, A. Penate, J. Melo, K. Capp, M. Gamez and R. Duara, Recovery from Proactive Semantic Interference in Mild Cognitive Impairment and Normal Aging: Relationship to Atrophy in Brain Regions Vulnerable to Alzheimer’s Disease (3) 1119–1126

Loewenstein, D.A., see Matías-Guiu, J.A. (2) 733–742

Longo, A., see Boccardi, V. (1) 239–248

Lopez, O.L., see Boada, M. (1) 129–143

Lott, I.T., see Doran, E. (2) 459–470

Louwersheimer, E., P.E. Cohn-Hokke, Y.A.L. Pijnenburg, M.M. Weiss, E.A. Sistermans, A.J. Rozemuller, M. Hulsman, J.C. van Swieten, C.M. van Duijn, F. Barkhof, T. Koene, P. Scheltens, W.M. Van der Flier and H. Holstege, Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer’s Disease in a Family with Several Generations of APOE-ɛ4 Homozygosity (1) 63–74

Lovestone, S., see Khan, W. (3) 1159–1174

Lu, X., see Chen, J. (2) 471–489

Lu, Y., Y. Dong, D. Tucker, R. Wang, M.E. Ahmed, D. Brann and Q. Zhang, Treadmill Exercise Exerts Neuroprotection and Regulates Microglial Polarization and Oxidative Stress in a Streptozotocin-Induced Rat Model of Sporadic Alzheimer’s Disease (4) 1469–1484

Lunn, M.P., see Toombs, J. (3) 885–891

Lyketsos, C., see Ismail, Z. (3) 929–938

Lyons, M.J., see Granholm, E.L. (4) 1419–1428

Magnani, G., ses Ferrari, L. (3) 1101–1107

Maikusa, N., see Fujishima, M. (1) 75–88

Maioli, S., see Persson, T. (2) 601–617

Majounie, E., see Morgan, A.R. (1) 25–36

Maki, P.M., see Sundermann, E.E. (3) 947–957

Maletta, R.G., see Ferrari, R. (4) 1271–1278

Manavis, J., see Chidlow, G. (2) 655–675

Manzo, V., see Carotenuto, A. (2) 805–815

Marelli, C., see Sellal, F. (1) 37–46

Marino, S., see Gareri, P. (2) 557–565

Marmarelis, V.Z., D.C. Shin, T. Tarumi and R. Zhang, Comparison of Model-Based Indices of Cerebral Autoregulation and Vasomotor Reactivity Using Transcranial Doppler versus Near-Infrared Spectroscopy in Patients with Amnestic Mild Cognitive Impairment (1) 89–105

Martinez-Almoyna, L., see Sellal, F. (1) 37–46

Martins, R.N., see Peters, K.E. (3) 1127–1133

Masters, C.L., see Khan, W. (3) 1159–1174

Masters, C.L., see Peters, K.E. (3) 1127–1133

Masters, C.L., see Sabbagh, M.N. (2) 441–446

Mateos-Vega, C.J., see González-Muñoz, M.J. (3) 917–927

Matías-Guiu, J., see Matías-Guiu, J.A. (2) 733–742

Matías-Guiu, J.A., R.E. Curiel, T. Rognoni, M. Valles-Salgado, M. Fernández-Matarrubia, R. Hariramani, A. Fernández-Castro, T. Moreno-Ramos, D.A. Loewenstein and J. Matías-Guiu, Validation of the Spanish Version of the LASSI-L for Diagnosing Mild Cognitive Impairment and Alzheimer’s Disease (2) 733–742

Matsuda, H., see Fujishima, M. (1) 75–88

Matsuda, T. and T. Hisatsune, Cholinergic Modification of Neurogenesis and Gliosis Improves the Memory of AβPPswe/PSEN1dE9 Alzheimer’s Disease Model Mice Fed a High-Fat Diet (1) 1–23

Matsui, D., see Kuriyama, N. (4) 1253–1262

Matsunaga, S., T. Kishi and N. Iwata, Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson’s Disease: A Meta-Analysis (4) 1229–1239

Matte, J.J., see Castellano, C.-A. (4) 1459–1468

Mäurer, A., see Apostolova, I. (1) 197–204

McKinnon, A.C., S.L. Duffy, N.E. Cross, Z. Terpening, R.R. Grunstein, J. Lagopoulos, J. Batchelor, I.B. Hickie, S.J.G. Lewis, J.M. Shine and S.L. Naismith, Functional Connectivity in the Default Mode Network is Reduced in Association with Nocturnal Awakening in Mild Cognitive Impairment (4) 1373–1384

McKinnon, C., see Kaizik, C. (3) 1109–1117

McLimans, K.E., A.A. Willette and for the Alzheimer’s Disease Neuroimaging Initiative, Autotaxin is Related to Metabolic Dysfunction and Predicts Alzheimer’s Disease Outcomes (1) 403–413

McNellis, B.M., see Liu, P. (2) 743–761

Mecocci, P., see Boccardi, V. (1) 239–248

Mecocci, P., see Khan, W. (3) 1159–1174

Meijboom, R., R.M.E. Steketee, L.S. Ham, A. van der Lugt, J.C. van Swieten and M. Smits, Differential Hemispheric Predilection of Microstructural White Matter and Functional Connectivity Abnormalities between Respectively Semantic and Behavioral Variant Frontotemporal Dementia (2) 789–804

Meiron, O., see Jaul, E. (3) 861–866

Melcangi, R.C., see Buccarello, L. (4) 1279–1292

Melo, J., see Loewenstein, D.A. (3) 1119–1126

Mendez, A.J., see Squitti, R. (3) 1055–1064

Mercken, M., see Timmers, M. (4) 1437–1449

Meseguer, I., see González-Muñoz, M.J. (3) 917–927

Meulenbroek, O., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Meysami, S., see Amen, D.G. (1) 261–273

Mézenge, F., see Gaubert, M. (2) 717–731

Meziere, A., see Zerah, L. (1) 145–156

Migliore, L., see Stoccoro, A. (4) 1451–1457

Miller, D.S., see Ismail, Z. (3) 929–938

Miné, M., see Sellal, F. (1) 37–46

Mioshi, E., see Kaizik, C. (3) 1109–1117

Mishra, S.K., see Shukla, V. (1) 335–349

Miyajima, M., see Jurjević, I. (1) 317–325

Mizuno, S., see Kuriyama, N. (4) 1253–1262

Mizuno, T., see Kuriyama, N. (4) 1253–1262

Moechars, D., see Timmers, M. (4) 1437–1449

Mohamed, L.A., H. Zhu, Y.M. Mousa, E. Wang, W.Q. Qiu and A. Kaddoumi, Amylin Enhances Amyloid-β Peptide Brain to Blood Efflux Across the Blood-Brain Barrier (3) 1087–1099

Molad, J., E. Kliper, A.D. Korczyn, E. Ben Assayag, D. Ben Bashat, S. Shenhar-Tsarfaty, O. Aizenstein, L. Shopin, N.M. Bornstein and E. Auriel, Only White Matter Hyperintensities Predicts Post-Stroke Cognitive Performances Among Cerebral Small Vessel Disease Markers: Results from the TABASCO Study (4) 1293–1299

Molinuevo, J.L., see Tell-Marti, G. (3) 1065–1074

Molinuevo, J.L., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Momeni, P., see Ferrari, R. (4) 1271–1278

Monacelli, F., A. Signori, L. Roffredo, K. Pace, A. Nencioni, G. Pickering, M. Nicolas and P. Odetti, Algoplus® Scale in Older Patients with Dementia: A Reliable Real-World Pain Assessment Tool (2) 519–527

Montag, C., see Kunz, L. (3) 1135–1144

Moreno-Ramos, T., see Matías-Guiu, J.A. (2) 733–742

Morgan, A.R., S. Touchard, C. O’Hagan, R. Sims, E. Majounie, V. Escott-Price, L. Jones, J. Williams and B.P. Morgan, The Correlation between Inflammatory Biomarkers and Polygenic Risk Score in Alzheimer’s Disease (1) 25–36

Morgan, B.P., see Morgan, A.R. (1) 25–36

Mortby, M.E., see Ismail, Z. (3) 929–938

Mousa, Y.M., see Mohamed, L.A. (3) 1087–1099

Muehlboeck, J.-S., see Khan, W. (3) 1159–1174

Muhs, A., see Theunis, C. (2) 585–599

Muñoz, J., see Boada, M. (1) 129–143

Murata, S., see Sugimoto, T. (2) 567–574

Murayama, S., see Sabbagh, M.N. (2) 441–446

N’Songo, A., M.M. Carrasquillo, X. Wang, T. Nguyen, Y. Asmann, S.G. Younkin, M. Allen, R. Duara, M.T. Greig Custo, N. Graff-Radford and N. Ertekin-Taner, Comprehensive Screening for Disease Risk Variants in Early-Onset Alzheimer’s Disease Genes in African Americans Identifies Novel PSEN Variants (4) 1215–1222

Na, D.L., see Chang, K.J. (4) 1341–1348

Nacmias, B., see Ferrari, R. (4) 1271–1278

Nacmias, B., see Stoccoro, A. (4) 1451–1457

Naglie, G., see Hird, M.A. (2) 447–452

Naismith, S.L., see McKinnon, A.C. (4) 1373–1384

Nakagawa, M., see Kuriyama, N. (4) 1253–1262

Nakajima, M., see Jurjević, I. (1) 317–325

Nakanishi, M., J. Niimura, S. Yamasaki and A. Nishida, Death of Dementia Patients in Psychiatric Hospitals and Regional Supply of Psychiatric Services: Study of the National Data from 1996 to 2014 in Japan (2) 817–824

Nees, F., see Khan, W. (3) 1159–1174

Nencioni, A., see Monacelli, F. (2) 519–527

Neri, C., see Zerah, L. (1) 145–156

Nguyen, T., see N’Songo, A. (4) 1215–1222

Ni, J., see Shen, L. (1) 361–378

Nicolas, G., see Sellal, F. (1) 37–46

Nicolas, M., see Monacelli, F. (2) 519–527

Niida, S., see Sugimoto, T. (2) 567–574

Niimura, J., see Nakanishi, M. (2) 817–824

Niisato, K., see Kamikubo, Y. (2) 641–653

Nishida, A., see Nakanishi, M. (2) 817–824

Nobili, A., see Gelfo, F. (4) 1505–1518

Nobili, F.M., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Noguchi, N., see Kotani, R. (2) 529–542

Noh, J.S., see Chang, K.J. (4) 1341–1348

Nørgaard, A., C. Jensen-Dahm, C. Gasse, E.S. Hansen and G. Waldemar, Psychotropic Polypharmacy in Patients with Dementia: Prevalence and Predictors (2) 707–716

Norredam, M., see Agyemang, C. (1) 205–213

Ntovas, K., see Zygouris, S. (2) 619–627

Núñez, L., see Boada, M. (1) 129–143

O’Connor, C.M., see Kaizik, C. (3) 1109–1117

O’Hagan, C., see Morgan, A.R. (1) 25–36

Obisesan, T.O., see Boada, M. (1) 129–143

Odetti, P., see Monacelli, F. (2) 519–527

Oesterlé, H., see Sellal, F. (1) 37–46

Ogino, I., see Jurjević, I. (1) 317–325

Oguz, K.K., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Oh, J.M., see Law, L.L. (1) 351–359

Öhman, H., see Kallio, E.-L. (4) 1349–1372

Okonkwo, O.C., see Law, L.L. (1) 351–359

Olazarán, J., see Boada, M. (1) 129–143

Ono, R., see Sugimoto, T. (2) 567–574

Onyike, C.U., see Ismail, Z. (3) 929–938

Orellana, J.M., see González-Muñoz, M.J. (3) 917–927

Oremus, M., see Fenesi, B. (1) 297–303

Ormaechea, J.F., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Ortiz, P., see Boada, M. (1) 129–143

Ostrowski, T.D., see Ebel, D.L. (3) 1197–1211

Oyebode, J.R., see Kaizik, C. (3) 1109–1117

Ozaki, E., see Kuriyama, N. (4) 1253–1262

Pace, K., see Monacelli, F. (2) 519–527

Padovani, A., see Ferrari, R. (4) 1271–1278

Páez, A., see Boada, M. (1) 129–143

Palluzzi, F., see Ferrari, R. (4) 1271–1278

Pang, W., see Tan, L. (2) 629–640

Panizzon, M.S., see Granholm, E.L. (4) 1419–1428

Pant, H.C., see Shukla, V. (1) 335–349

Pantoni, L., see Valenti, R. (4) 1223–1227

Pappagallo, A.S., see Ienca, M. (4) 1301–1340

Paquet, N., see Castellano, C.-A. (4) 1459–1468

Park, J., see Chang, K.J. (4) 1341–1348

Park, Y.S., see Kim, Y.J. (3) 1007–1014

Parnetti, L., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Pasinetti, G.M., see Ho, L. (1) 305–315

Paterson, R.W., see Toombs, J. (3) 885–891

Paus, T., see Khan, W. (3) 1159–1174

Pausova, Z., see Khan, W. (3) 1159–1174

Peña-Fernández, A., see González-Muñoz, M.J. (3) 917–927

Penate, A., see Loewenstein, D.A. (3) 1119–1126

Peng, Y., see Li, L. (4) 1403–1417

Pereira, J., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Pericak-Vance, M.A., see Haddick, P.C.G. (3) 1037–1054

Perrotin, A., see Gaubert, M. (2) 717–731

Persson, T., F. Lattanzio, J. Calvo-Garrido, R. Rimondini, M. Rubio-Rodrigo, E. Sundström, S. Maioli, A. Sandebring-Matton and Á. Cedazo-Mínguez, Apolipoprotein E4 Elicits Lysosomal Cathepsin D Release, Decreased Thioredoxin-1 Levels, and Apoptosis (2) 601–617

Pestilli, F., see Glozman, T. (1) 287–295

Peters, K.E., W.A. Davis, K. Taddei, R.N. Martins, C.L. Masters, T.M.E. Davis and D.G. Bruce, Plasma Amyloid-β Peptides in Type 2 Diabetes: A Matched Case-Control Study (3) 1127–1133

Peters, O., see Sabbagh, M.N. (2) 441–446

Peters, R., see Anstey, K.J. (1) 215–228

Petrella, R.J., see Heath, M. (1) 167–183

Petrosini, L., see Gelfo, F. (4) 1505–1518

Pfeifer, A., see Theunis, C. (2) 585–599

Phelan, M.J., see Doran, E. (2) 459–470

Phung, Q.T., see Haddick, P.C.G. (3) 1037–1054

Piaceri, I., see Ferrari, R. (4) 1271–1278

Piaz, F.D., see Benussi, L. (2) 825–833

Picco, A., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Picher, A.J., see Gomez-Ramos, A. (3) 977–990

Pickering, G., see Monacelli, F. (2) 519–527

Pierce, A., see Grill, J.D. (3) 939–946

Pietrzik, C.U., see Brandscheid, C. (2) 775–788

Piguet, O., see Kaizik, C. (3) 1109–1117

Pihlgren, M., see Theunis, C. (2) 585–599

Pijnenburg, Y.A.L., see Louwersheimer, E. (1) 63–74

Pikkarainen, M., see Suhonen, N.-M. (4) 1241–1251

Pikkarainen, M., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Pimouguet, C., M.L. Goff, J. Wittwer, J.-F. Dartigues and C. Helmer, Benefits of Occupational Therapy in Dementia Patients: Findings from a Real-World Observational Study (2) 509–517

Pinessi, L., see Ferrari, R. (4) 1271–1278

Piorkowska, K., see Theunis, C. (2) 585–599

Pitkälä, K., see Kallio, E.-L. (4) 1349–1372

Plana, E., see Tell-Marti, G. (3) 1065–1074

Polcher, A., I. Frommann, A. Koppara, S. Wolfsgruber, F. Jessen and M. Wagner, Face-Name Associative Recognition Deficits in Subjective Cognitive Decline and Mild Cognitive Impairment (3) 1185–1196

Potkin, S.G., see Doran, E. (2) 459–470

Potrony, M., see Tell-Marti, G. (3) 1065–1074

Prasad, V., see Apostolova, I. (1) 197–204

Prins, N.D., see Van Mierlo, L.D. (1) 249–259

Puig, S., see Tell-Marti, G. (3) 1065–1074

Puig-Butille, J.A., see Tell-Marti, G. (3) 1065–1074

Putignano, D., see Gareri, P. (2) 557–565

Putignano, S., see Gareri, P. (2) 557–565

Qiu, W.Q., see Mohamed, L.A. (3) 1087–1099

Qiu, W.Q., see Wang, E. (1) 47–61

Querfurth, H.W., see Lee, H.-K. (3) 1015–1036

Raffo, A., see Loewenstein, D.A. (3) 1119–1126

Raghavendra, C.S., see Amen, D.G. (1) 261–273

Raina, P., see Fenesi, B. (1) 297–303

Rainero, I., see Ferrari, R. (4) 1271–1278

Raji, C.A., see Amen, D.G. (1) 261–273

Rao, E.R., see Liu, P. (2) 743–761

Rasgon, N., see Sabbagh, M.N. (2) 441–446

Rathore, N., see Haddick, P.C.G. (3) 1037–1054

Rauchs, G., see Gaubert, M. (2) 717–731

Raux, M., see Zerah, L. (1) 145–156

Rea, R., see Carotenuto, A. (2) 805–815

Reddy, P., see Shukla, V. (1) 335–349

Reichl, J.H., see Liu, P. (2) 743–761

Reijmer, Y.D., see Valenti, R. (4) 1223–1227

Reinhardt, S., see Brandscheid, C. (2) 775–788

Remes, A.M., see Suhonen, N.-M. (4) 1241–1251

Reuter, M., see Kunz, L. (3) 1135–1144

Riant, F., see Sellal, F. (1) 37–46

Ricard-Blum, S., see Salza, R. (3) 991–1005

Ricci, G., see Carotenuto, A. (2) 805–815

Richards, D., see Sabbagh, M.N. (2) 441–446

Ricordi, C., see Squitti, R. (3) 1055–1064

Rietschel, M., see Khan, W. (3) 1159–1174

Riley, G., see Valenti, R. (4) 1223–1227

Rimondini, R., see Persson, T. (2) 601–617

Riou, B., see Zerah, L. (1) 145–156

Rissman, R.A., see Sokolow, S. (1) 229–237

Roberts, A., see Apostolova, I. (1) 197–204

Roffredo, L., see Monacelli, F. (2) 519–527

Rognoni, T., see Matías-Guiu, J.A. (2) 733–742

Romano, C., see Stoccoro, A. (4) 1451–1457

Ronowska, A., see Zyśk, M. (3) 1145–1158

Rosand, J., see Sellal, F. (1) 37–46

Rosenberg, P.B., see Ismail, Z. (3) 929–938

Rossi, G., see Ferrari, R. (4) 1271–1278

Rotter, J.I., see Sokolow, S. (1) 229–237

Rousseau, S., see Sellal, F. (1) 37–46

Rovelet-Lecrux, A., see Sellal, F. (1) 37–46

Rowe, C.C., see Sabbagh, M.N. (2) 441–446

Rozemuller, A.J., see Louwersheimer, E. (1) 63–74

Rubin, L.H., see Sundermann, E.E. (3) 947–957

Rubino, E., see Ferrari, R. (4) 1271–1278

Rubio-Rodrigo, M., see Persson, T. (2) 601–617

Ruggiero, C., see Boccardi, V. (1) 239–248

Sabbagh, M.N., B. Schäuble, K. Anand, D. Richards, S. Murayama, H. Akatsu, M. Takao, C.C. Rowe, C.L. Masters, H. Barthel, H.-J. Gertz, O. Peters, N. Rasgon, A. Jovalekic, O. Sabri, W.J. Schulz-Schaeffer and J. Seibyl, Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimer’s Disease (2) 441–446

Sabri, O., see Sabbagh, M.N. (2) 441–446

Sager, M.A., see Law, L.L. (1) 351–359

Saji, N., see Sugimoto, T. (2) 567–574

Saka, E., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Sakowicz-Burkiewicz, M., see Zyśk, M. (3) 1145–1158

Sakurai, T., see Kamikubo, Y. (2) 641–653

Sakurai, T., see Sugimoto, T. (2) 567–574

Salluzzo, M.G., see Stoccoro, A. (4) 1451–1457

Salvadori, N., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Salza, R., C. Lethias and S. Ricard-Blum, The Multimerization State of the Amyloid-β42 Peptide (Aβ42) Governs its Interaction Network with the Extracellular Matrix (3) 991–1005

Sánchez-Muniz, F.J., see González-Muñoz, M.J. (3) 917–927

Sanchez-Valle, R., see Tell-Marti, G. (3) 1065–1074

Sanchez-Valle, R., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Sandebring-Matton, A., see Persson, T. (2) 601–617

Santamaria, F., see Gareri, P. (2) 557–565

Santana, I., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Scarpini, E., see Ferrari, R. (4) 1271–1278

Scarpini, E., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Schäfer, K.-H., see Brandscheid, C. (2) 775–788

Schäuble, B., see Sabbagh, M.N. (2) 441–446

Schellenberg, G.D., see Haddick, P.C.G. (3) 1037–1054

Scheltens, P., see Louwersheimer, E. (1) 63–74

Scheltens, P., see Slot, R.E.R. (2) 687–697

Scheltens, P., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Schneider, J., see Yarchoan, M. (2) 699–706

Schneider, J.A., see Yu, L. (4) 1485–1493

Schott, J.M., see Toombs, J. (3) 885–891

Schreurs, B.G., see Brooks, S.W. (1) 185–196

Schuck, F., see Brandscheid, C. (2) 775–788

Schultz, S.A., see Law, L.L. (1) 351–359

Schulz-Schaeffer, W.J., see Sabbagh, M.N. (2) 441–446

Schumann, G., see Khan, W. (3) 1159–1174

Schweizer, T.A., see Hird, M.A. (2) 447–452

Schwiertz, A., see Brandscheid, C. (2) 775–788

Segkouli, S., see Zygouris, S. (2) 619–627

Seibyl, J., see Sabbagh, M.N. (2) 441–446

Seixas, A., see Agyemang, C. (1) 205–213

Selfe, T.K., see Innes, K.E. (3) 899–916

Sellal, F., D. Wallon, L. Martinez-Almoyna, C. Marelli, A. Dhar, H. Oesterlé, A. Rovelet-Lecrux, S. Rousseau, C.E. Kourkoulis, J. Rosand, Z.Y. DiPucchio, M. Frosch, C. Gombert, B. Audoin, M. Miné, F. Riant, T. Frebourg, D. Hannequin, D. Campion, S.M. Greenberg, E. Tournier-Lasserve and G. Nicolas, APP Mutations in Cerebral Amyloid Angiopathy with or without Cortical Calcifications: Report of Three Families and a Literature Review (1) 37–46

Seo, J., see Shukla, V. (1) 335–349

Seo, S.W., see Chang, K.J. (4) 1341–1348

Serpente, M., see Ferrari, R. (4) 1271–1278

Sha, L., see Wu, L. (3) 893–898

Shah, R.C., see Yarchoan, M. (2) 699–706

Shaw, L.M., see Timmers, M. (4) 1437–1449

Shellington, E., see Heath, M. (1) 167–183

Shen, L., L. Liao, C. Chen, Y. Guo, D. Song, Y. Wang, Y. Chen, K. Zhang, M. Ying, S. Li, Q. Liu and J. Ni, Proteomics Analysis of Blood Serums from Alzheimer’s Disease Patients Using iTRAQ Labeling Technology (1) 361–378

Shen, L., L. Liu and H.-F. Ji, Alzheimer’s Disease Histological and Behavioral Manifestations in Transgenic Mice Correlate with Specific Gut Microbiome State (1) 385–390

Shenhar-Tsarfaty, S., see Molad, J. (4) 1293–1299

Shi, L., see Jia, J. (4) 1495–1504

Shin, D.C., see Marmarelis, V.Z. (1) 89–105

Shine, J.M., see McKinnon, A.C. (4) 1373–1384

Shopin, L., see Molad, J. (4) 1293–1299

Shu, H., see Su, F. (2) 491–507

Shu, H., see Wang, Z. (1) 415–428

Shua-Haim, J.R., see Boada, M. (1) 129–143

Shukla, V., J. Seo, B.K. Binukumar, N.D. Amin, P. Reddy, P. Grant, S. Kuntz, S. Kesavapany, J. Steiner, S.K. Mishra, L.-H. Tsai and H.C. Pant, TFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice (1) 335–349

Siciliano, G., see Stoccoro, A. (4) 1451–1457

Siegel, A.M., M.S. Barrett and M.T. Bhati, Deep Brain Stimulation for Alzheimer’s Disease: Ethical Challenges for Clinical Research (2) 429–436

Signori, A., see Monacelli, F. (2) 519–527

Sikkes, S.A.M., see Van Mierlo, L.D. (1) 249–259

Simmons, A., see Khan, W. (3) 1159–1174

Simonelli, I., see Squitti, R. (3) 1055–1064

Sims, R., see Morgan, A.R. (1) 25–36

Singleton, A., see Ferrari, R. (4) 1271–1278

Sistermans, E.A., see Louwersheimer, E. (1) 63–74

Slemmon, J., see Timmers, M. (4) 1437–1449

Slot, R.E.R., A.C. Van Harten, M.I. Kester, W. Jongbloed, F.H. Bouwman, C.E. Teunissen, P. Scheltens, R. Veerhuis and W.M. van der Flier, Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer’s Disease in Non-Demented Elderly (2) 687–697

Small, G.W., see Doran, E. (2) 459–470

Smirne, N., see Boccardi, V. (1) 239–248

Smith, E.E., see Ismail, Z. (3) 929–938

Smith, G.S., see Ismail, Z. (3) 929–938

Smits, M., see Meijboom, R. (2) 789–804

Smolka, M.N., see Khan, W. (3) 1159–1174

Soennesyn, H., see Bergland, A.K. (2) 575–584

Soininen, H., see Imtiaz, B. (2) 453–458

Soininen, H., see Khan, W. (3) 1159–1174

Soininen, H., see Suhonen, N.-M. (4) 1241–1251

Soininen, H., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Sokolow, S., X. Li, L. Chen, K.D. Taylor, J.I. Rotter, R.A. Rissman, P.S. Aisen and L.G. Apostolova, Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment (1) 229–237

Solomon, A., see Imtiaz, B. (2) 453–458

Solomon, J., see Glozman, T. (1) 287–295

Son, S.J., see Chang, K.J. (4) 1341–1348

Song, D., see Shen, L. (1) 361–378

Song, N., see Tan, L. (2) 629–640

Song, Y.-Q., see Lin, T.-S. (3) 959–976

Soriano, E., see Gomez-Ramos, A. (3) 977–990

Spenger, C., see Khan, W. (3) 1159–1174

Squitti, R., A.J. Mendez, I. Simonelli and C. Ricordi, Diabetes and Alzheimer’s Disease: Can Elevated Free Copper Predict the Risk of the Disease? (3) 1055–1064

Srinivasan, K., see Haddick, P.C.G. (3) 1037–1054

Ståhlbom, A.K., see Li, X. (1) 327–334

Stechl, E., see Apostolova, I. (1) 197–204

Stein, J.H., see Law, L.L. (1) 351–359

Steiner, J., see Shukla, V. (1) 335–349

Steinhagen-Thiessen, E., see Apostolova, I. (1) 197–204

Steketee, R.M.E., see Meijboom, R. (2) 789–804

Stoccoro, A., P. Tannorella, M.G. Salluzzo, R. Ferri, C. Romano, B. Nacmias, G. Siciliano, L. Migliore and F. Coppedè, The Methylenetetrahydrofolate Reductase C677T Polymorphism and Risk for Late-Onset Alzheimer’s disease: Further Evidence in an Italian Multicenter Study (4) 1451–1457

Streffer, J.R., see Timmers, M. (4) 1437–1449

Ströhle, A., see Khan, W. (3) 1159–1174

Stronks, K., see Agyemang, C. (1) 205–213

Su, F., H. Shu, Q. Ye, C. Xie, B. Yuan, Z. Zhang and F. Bai, Integration of Multilocus Genetic Risk into the Default Mode Network Longitudinal Trajectory during the Alzheimer’s Disease Process (2) 491–507

Sugimoto, H., see Kotani, R. (2) 529–542

Sugimoto, T., M. Yoshida, R. Ono, S. Murata, N. Saji, S. Niida, K. Toba and T. Sakurai, Frontal Lobe Function Correlates with One-Year Incidence of Urinary Incontinence in Elderly with Alzheimer Disease (2) 567–574

Suhonen, N.-M., I. Hallikainen, T. Hänninen, J. Jokelainen, J. Krüger, A. Hall, M. Pikkarainen, H. Soininen and A.M. Remes, The Modified Frontal Behavioral Inventory (FBI-mod) for Patients with Frontotemporal Lobar Degeneration, Alzheimer’s Disease, and Mild Cognitive Impairment (4) 1241–1251

Sultzer, D.L., see Ismail, Z. (3) 929–938

Sun, N., see Chen, J. (2) 471–489

Sun, S., see Tan, L. (2) 629–640

Sun, X., see Loewenstein, D.A. (3) 1119–1126

Sundermann, E.E., A. Biegon, L.H. Rubin, R.B. Lipton, S. Landau and P.M. Maki for the Alzheimer’s Disease Neuroimaging Initiative, Does the Female Advantage in Verbal Memory Contribute to Underestimating Alzheimer’s Disease Pathology in Women versus Men? (3) 947–957

Sundström, E., see Persson, T. (2) 601–617

Szűcs, A., see Horváth, A. (3) 1175–1183

Szutowicz, A., see Zyśk, M. (3) 1145–1158

Taddei, K., see Peters, K.E. (3) 1127–1133

Tagliavini, F., see Ferrari, R. (4) 1271–1278

Taipale, H., see Koponen, M. (1) 107–118

Taipale, H., see Lampela, P. (1) 119–128

Takada, A., see Kuriyama, N. (4) 1253–1262

Takao, M., see Sabbagh, M.N. (2) 441–446

Takasugi, N., see Kamikubo, Y. (2) 641–653

Takeda, K., see Kuriyama, N. (4) 1253–1262

Tamura, A., see Kuriyama, N. (4) 1253–1262

Tan, L., H. Yang, W. Pang, H. Li, W. Liu, S. Sun, N. Song, W. Zhang and Y. Jiang, Investigation on the Role of BDNF in the Benefits of Blueberry Extracts for the Improvement of Learning and Memory in Alzheimer’s Disease Mouse Model (2) 629–640

Tang, Y., see Jia, J. (4) 1495–1504

Tannorella, P., see Stoccoro, A. (4) 1451–1457

Tanskanen, A., see Koponen, M. (1) 107–118

Tanskanen, A., see Lampela, P. (1) 119–128

Tapias, V., see Fitz, N.F. (3) 1075–1085

Tarducci, R., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Tárraga, L., see Boada, M. (1) 129–143

Tarumi, T., see Marmarelis, V.Z. (1) 89–105

Taylor, K.D., see Sokolow, S. (1) 229–237

Tell-Marti, G., J.A. Puig-Butille, M. Potrony, E. Plana, C. Badenas, A. Antonell, R. Sanchez-Valle, J.L. Molinuevo, A. Lleó, D. Alcolea, J. Fortea, R. Fernández-Santiago, J. Clarimón, A. Lladó and S. Puig, A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer’s Disease Risk (3) 1065–1074

Terpening, Z., see McKinnon, A.C. (4) 1373–1384

Tesseur, I., see Timmers, M. (4) 1437–1449

Teunissen, C., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Teunissen, C.E., see Slot, R.E.R. (2) 687–697

Theunis, C., O. Adolfsson, N. Crespo-Biel, K. Piorkowska, M. Pihlgren, D.T. Hickman, V. Gafner, P. Borghgraef, H. Devijver, A. Pfeifer, F. Van Leuven and A. Muhs, Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope (2) 585–599

Thevarkunnel, S., see Borghys, H. (2) 763–774

Thordardottir, S., see Li, X. (1) 327–334

Thygesen, L.C., L.N. Gimsing, A. Bautz, N.C. Hvidt and C. Johansen, Chronic Neurodegenerative Illnesses and Epilepsy in Danish Adventists and Baptists: A Nationwide Cohort Study (4) 1429–1435

Tiihonen, J., see Koponen, M. (1) 107–118

Tiihonen, J., see Lampela, P. (1) 119–128

Timmers, M., S. Barão, B. Van Broeck, I. Tesseur, J. Slemmon, K. De Waepenaert, J. Bogert, L.M. Shaw, S. Engelborghs, D. Moechars, M. Mercken, L. Van Nueten, L. Tritsmans, B. de Strooper and J.R. Streffer BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants (4) 1437–1449

Titheridge, S., see Heath, M. (1) 167–183

Toba, K., see Sugimoto, T. (2) 567–574

Tokuda, T., see Kuriyama, N. (4) 1253–1262

Tolppanen, A.M., see Imtiaz, B. (2) 453–458

Tolppanen, A.-M., see Koponen, M. (1) 107–118

Tolppanen, A.-M., see Lampela, P. (1) 119–128

Toombs, J., M.S. Foiani, R.W. Paterson, A. Heslegrave, S. Wray, J.M. Schott, N.C. Fox, M.P. Lunn, K. Blennow and H. Zetterberg, Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-β Concentration (3) 885–891

Torkilsen, C.G., see Ebel, D.L. (3) 1197–1211

Torres, M., see Boada, M. (1) 129–143

Totoiu, M., see Doran, E. (2) 459–470

Touchard, S., see Morgan, A.R. (1) 25–36

Tourette, C., see Zerah, L. (1) 145–156

Tournier-Lasserve, E., see Sellal, F. (1) 37–46

Traini, E., see Carotenuto, A. (2) 805–815

Tremblay, S., see Castellano, C.-A. (4) 1459–1468

Tritsmans, L., see Timmers, M. (4) 1437–1449

Tsai, H.-J., see Lin, T.-S. (3) 959–976

Tsai, L.-H., see Shukla, V. (1) 335–349

Tsolaki, M., see Khan, W. (3) 1159–1174

Tsolaki, M., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Tsolaki, M., see Zygouris, S. (2) 619–627

Tucker, D., see Lu, Y. (4) 1469–1484

Tufts, E., see Last, N. (1) 275–286

Tzovaras, D., see Zygouris, S. (2) 619–627

Urano, Y., see Kotani, R. (2) 529–542

Urbani, A., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Vaartjes, I., see Agyemang, C. (1) 205–213

Valcarcel, B., see Ho, L. (1) 305–315

Valenti, R., A. Charidimou, L. Xiong, G. Boulouis, P. Fotiadis, A. Ayres, G. Riley, H.J. Kuijf, Y.D. Reijmer, L. Pantoni, M.E. Gurol, S. Davidsdottir, S.M. Greenberg and A. Viswanathan, Visuospatial Functioning in Cerebral Amyloid Angiopathy: A Pilot Study (4) 1223–1227

Valles-Salgado, M., see Matías-Guiu, J.A. (2) 733–742

Van Broeck, B., see Borghys, H. (2) 763–774

Van Broeck, B., see Timmers, M. (4) 1437–1449

van de Vorst, I.E., see Agyemang, C. (1) 205–213

van der Brug, M., see Haddick, P.C.G. (3) 1037–1054

Van der Flier, W.M., see Louwersheimer, E. (1) 63–74

van der Flier, W.M., see Slot, R.E.R. (2) 687–697

Van der Flier, W.M., see Van Mierlo, L.D. (1) 249–259

van der Lugt, A., see Meijboom, R. (2) 789–804

van Duijn, C.M., see Louwersheimer, E. (1) 63–74

Van Harten, A.C., see Slot, R.E.R. (2) 687–697

Van Hout, H.P.J., see Van Mierlo, L.D. (1) 249–259

Van Leuven, F., see Theunis, C. (2) 585–599

Van Mierlo, L.D., H. Wouters, S.A.M. Sikkes, W.M. Van der Flier, N.D. Prins, J.A.E. Bremer, T. Koene and H.P.J. Van Hout, Screening for Mild Cognitive Impairment and Dementia with Automated, Anonymous Online and Telephone Cognitive Self-Tests (1) 249–259

Van Nueten, L., see Timmers, M. (4) 1437–1449

van Swieten, J.C., see Louwersheimer, E. (1) 63–74

van Swieten, J.C., see Meijboom, R. (2) 789–804

van Waalwijk van Doorn, L.J.C., J.D. Gispert, H.B. Kuiperij, J.A.H.R. Claassen, A. Arighi, I. Baldeiras, K. Blennow, M. Bozzali, M. Castelo-Branco, E. Cavedo, D.D. Emek-Savaş, E. Eren, P. Eusebi, L. Farotti, C. Fenoglio, J.F. Ormaechea, Y. Freund-Levi, G.B. Frisoni, D. Galimberti, S. Genc, V. Greco, H. Hampel, S.-K. Herukka, Y. Liu, A. Lladó, A. Lleó, F.M. Nobili, K.K. Oguz, L. Parnetti, J. Pereira, A. Picco, M. Pikkarainen, C.R. de Oliveira, E. Saka, N. Salvadori, R. Sanchez-Valle, I. Santana, E. Scarpini, P. Scheltens, H. Soininen, R. Tarducci, C. Teunissen, M. Tsolaki, A. Urbani, E. Vilaplana, P.J. Visser, A.K. Wallin, G. Yener, J.L. Molinuevo, O. Meulenbroek and M.M. Verbeek, Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer’s Disease Patients and Controls after Correction for Ventricular Volumes (2) 543–555

Vasiliev, A.V., see Dashinimaev, E.B. (2) 835–847

Vassar, R., see Liu, P. (2) 743–761

Veerhuis, R., see Slot, R.E.R. (2) 687–697

Vellas, B., see Khan, W. (3) 1159–1174

Verbeek, M.M., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Verny, M., see Zerah, L. (1) 145–156

Vesely, K.A., see Hird, M.A. (2) 447–452

Vilaplana, E., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Villain, N., see Gaubert, M. (2) 717–731

Villemagne, V.L., see Khan, W. (3) 1159–1174

Visser, P.J., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Viswanathan, A., see Valenti, R. (4) 1223–1227

Vorotelyak, E.A., see Dashinimaev, E.B. (2) 835–847

Votis, K., see Zygouris, S. (2) 619–627

Wagner, M., see Polcher, A. (3) 1185–1196

Wahlund, L.-O., see Khan, W. (3) 1159–1174

Wahlund, L.-O., see Li, X. (1) 327–334

Waldemar, G., see Nørgaard, A. (2) 707–716

Wallack, M., see Wang, E. (1) 47–61

Wallin, A.K., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Wallon, D., see Sellal, F. (1) 37–46

Wang, E., H. Zhu, X. Wang, A.C. Gower, M. Wallack, J.K. Blusztajn, N. Kowall and W.Q. Qiu, Amylin Treatment Reduces Neuroinflammation and Ameliorates Abnormal Patterns of Gene Expression in the Cerebral Cortex of an Alzheimer’s Disease Mouse Model (1) 47–61

Wang, E., see Mohamed, L.A. (3) 1087–1099

Wang, H., X. Hong and Y. Wang, Mitochondrial Repair Effects of Oxygen Treatment on Alzheimer’s Disease Model Mice Revealed by Quantitative Proteomics (3) 875–883

Wang, L., see Li, L. (4) 1403–1417

Wang, Q., W.-X. Li, S.-X. Dai, Y.-C. Guo, F.-F. Han, J.-J. Zheng, G.-H. Li and J.-F. Huang, Meta-Analysis of Parkinson’s Disease and Alzheimer’s Disease Revealed Commonly Impaired Pathways and Dysregulation of NRF2-Dependent Genes (4) 1525–1539

Wang, R., see Lu, Y. (4) 1469–1484

Wang, X., see Li, L. (4) 1403–1417

Wang, X., see N’Songo, A. (4) 1215–1222

Wang, X., see Wang, E. (1) 47–61

Wang, X., see Wu, L. (3) 893–898

Wang, Y., see Shen, L. (1) 361–378

Wang, Y., see Wang, H. (3) 875–883

Wang, Z., Z. Dai, H. Shu, D. Liu, Q. Guo, Y. He and Z. Zhang, Cortical Thickness and Microstructural White Matter Changes Detect Amnestic Mild Cognitive Impairment (1) 415–428

Wangmo, T., see Ienca, M. (4) 1301–1340

Watanabe, I., see Kuriyama, N. (4) 1253–1262

Watanabe, Y., see Kuriyama, N. (4) 1253–1262

Watts, R.J., see Haddick, P.C.G. (3) 1037–1054

Wei, C., see Jia, J. (4) 1495–1504

Weiss, M.M., see Louwersheimer, E. (1) 63–74

Westman, E., see Khan, W. (3) 1159–1174

Westman, E., see Li, X. (1) 327–334

Willette, A.A., see McLimans, K.E. (1) 403–413

Williams, J., see Morgan, A.R. (1) 25–36

Williams, S.C.R., see Khan, W. (3) 1159–1174

Wilson, R.S., see Yarchoan, M. (2) 699–706

Wilson, R.S., see Yu, L. (4) 1485–1493

Wittwer, J., see Pimouguet, C. (2) 509–517

Wolfsgruber, S., see Polcher, A. (3) 1185–1196

Wood, J.P.M., see Chidlow, G. (2) 655–675

Wouters, H., see Van Mierlo, L.D. (1) 249–259

Wray, S., see Toombs, J. (3) 885–891

Wright, C., see Loewenstein, D.A. (3) 1119–1126

Wright, C.E., see Betrie, A.H. (2) 849–860

Wu, L., J. Liu, L. Sha, X. Wang, J. Li, J. Dong and J. Jia, Sporadic Cases with Novel Mutations and Pedigree in Hereditary Leukoencephalopathy with Axonal Spheroids (3) 893–898

Xiao, C., see Chen, J. (2) 471–489

Xie, B., Y. Xu, Z. Liu, W. Liu, L. Jiang, R. Zhang, D. Cui, Q. Zhang and S. Xu, Elevation of Peripheral BDNF Promoter Methylation Predicts Conversion from Amnestic Mild Cognitive Impairment to Alzheimer’s Disease: A 5-Year Longitudinal Study (1) 391–401

Xie, C., see Su, F. (2) 491–507

Xiong, L., see Valenti, R. (4) 1223–1227

Xu, J., see Hu, C. (4) 1263–1269

Xu, S., see Li, L. (4) 1403–1417

Xu, S., see Xie, B. (1) 391–401

Xu, X., see Hu, C. (4) 1263–1269

Xu, Y., see Xie, B. (1) 391–401

Yamada, K., see Kuriyama, N. (4) 1253–1262

Yamasaki, S., see Nakanishi, M. (2) 817–824

Yang, H., see Tan, L. (2) 629–640

Yarchoan, M., B.D. James, R.C. Shah, Z. Arvanitakis, R.S. Wilson, J. Schneider, D.A. Bennett and S.E. Arnold, Association of Cancer History with Alzheimer’s Disease Dementia and Neuropathology (2) 699–706

Ye, Q., see Su, F. (2) 491–507

Yener, G., see van Waalwijk van Doorn, L.J.C. (2) 543–555

Ying, M., see Shen, L. (1) 361–378

Yoshida, M., see Sugimoto, T. (2) 567–574

Younesi, E., see Emon, M.A.E.K. (2) 677–686

Younkin, S.G., see N’Songo, A. (4) 1215–1222

Yu, L., R.S. Wilson, J.A. Schneider, D.A. Bennett and P.A. Boyle, Financial and Health Literacy Predict Incident Alzheimer’s Disease Dementia and Pathology (4) 1485–1493

Yuan, B., see Su, F. (2) 491–507

Zahs, K.R., see Liu, P. (2) 743–761

Zeng, L., see Hu, C. (4) 1263–1269

Zerah, L., J. Cohen-Bittan, M. Raux, A. Meziere, C. Tourette, C. Neri, M. Verny, B. Riou, F. Khiami and J. Boddaert, Association between Cognitive Status before Surgery and Outcomes in Elderly Patients with Hip Fracture in a Dedicated Orthogeriatric Care Pathway (1) 145–156

Zetterberg, H., see Toombs, J. (3) 885–891

Zhan, L., see Chen, J. (2) 471–489

Zhang, K., see Shen, L. (1) 361–378

Zhang, Q., see Lu, Y. (4) 1469–1484

Zhang, Q., see Xie, B. (1) 391–401

Zhang, R., see Marmarelis, V.Z. (1) 89–105

Zhang, R., see Xie, B. (1) 391–401

Zhang, W., see Tan, L. (2) 629–640

Zhang, Z., see Su, F. (2) 491–507

Zhang, Z., see Wang, Z. (1) 415–428

Zhao, X., see Li, L. (4) 1403–1417

Zheng, J.-J., see Wang, Q. (4) 1525–1539

Zhou, A., see Jia, J. (4) 1495–1504

Zhu, H., see Mohamed, L.A. (3) 1087–1099

Zhu, H., see Wang, E. (1) 47–61

Zygouris, S., K. Ntovas, D. Giakoumis, K. Votis, S. Doumpoulakis, S. Segkouli, C. Karagiannidis, D. Tzovaras and M. Tsolaki, A Preliminary Study on the Feasibility of Using a Virtual Reality Cognitive Training Application for Remote Detection of Mild Cognitive Impairment (2) 619–627

Zyśk, M., H. Bielarczyk, S. Gul-Hinc, A. Dyś, B. Gapys, A. Ronowska, M. Sakowicz-Burkiewicz and A. Szutowicz, Phenotype-Dependent Interactions between N-acetyl-L-Aspartate and Acetyl-CoA in Septal SN56 Cholinergic Cells Exposed to an Excess of Zinc (3) 1145–1158